Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 2/20 | 0.42 |
| ▸ | TGM2 | P21980 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16217846 | 1.00 | LMNA (0.61) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL1389482 | 1.00 | LMNA (0.61) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL31400163 | 1.00 | LMNA (0.61) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL31400167 | 1.00 | LMNA (0.61) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL17448305 | 1.00 | LMNA (0.61) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL28746997 | 1.00 | LMNA (0.61) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL23217930 | 0.99 | LMNA (0.62) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL22855322 | 0.97 | LMNA (0.63) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL28747003 | 0.97 | LMNA (0.63) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL24699874 | 0.97 | LMNA (0.63) | LMNAKMT2APOLBCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210054017-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS INC (US) | 2021-02-25 | — | — | US | disclosed |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-10570169-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2015188194-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015179693-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210054017-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, FUT6, GALNT13 | LMNA 950/4885KMT2A 1558/4885POLB 544/4885 |
| US-10570169-B2 | Conjugated antisense compounds and their use | GNE, GALNT1, GALNT6 | LMNA 843/4885KMT2A 1653/4885POLB 570/4885 |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | LMNA 703/4885KMT2A 3802/4885POLB 3519/4885 |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | LMNA 703/4885KMT2A 3802/4885POLB 3519/4885 |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, GALNT1, GALNT6 | LMNA 843/4885KMT2A 1653/4885POLB 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.